Abstract #4264

Determination of the fate of intravenously administered Gd(III)DOTA-DSPE-based liposomal contrast agent in a mouse model

ERIC A TANIFUM^1,2, Conelius Ngwa³, Laxman Devkota³, Andrew A Badachhape³, Ketan B Ghaghada^3,4, Prajwal Bhandari², Igor Stupin⁴, Mayank Srivastava⁴, and Ananth V Annapragada^1,2

¹Pediatric Radiology, Texas Children's Hospital, Houston, TX, United States, ²Radiology, Baylor College of Medicine, Houston, TX, United States, ³Baylor College of Medicine, Houston, TX, United States, ⁴Texas Children's Hospital, Houston, TX, United States

Small molecule conventional gadolinium (Gd) present some safety concerns including nephrogenic systemic fibrosis (NSF) and brain accumulation. Nanoparticle-based gadolinium (Gd) agents may alleviate these concerns by streamlining the clearance pathways of the agent.Liposomal Gd(III)DOTA-DSPE conjugate exhibit high relaxivity at clinically-relevant MR field strength, and enables molecular MR imaging mice. We report herein an investigation on the pharmacokinetics, bio-distribution and clearance of a liposomal-Gd agent in mice over a period of 28 days by T1-weighted MR imaging and ICP-MS analyses. Results show no significant skin or brain accumulation, suggesting NSF and brain accumulation concerns may be unlikely with such agent.

This abstract and the presentation materials are available to members only; a login is required.

Join Here